BR0312988A - Microcápsulas com liberação modificada de princìpios ativos pouco solúveis para a administração per os - Google Patents

Microcápsulas com liberação modificada de princìpios ativos pouco solúveis para a administração per os

Info

Publication number
BR0312988A
BR0312988A BR0312988-8A BR0312988A BR0312988A BR 0312988 A BR0312988 A BR 0312988A BR 0312988 A BR0312988 A BR 0312988A BR 0312988 A BR0312988 A BR 0312988A
Authority
BR
Brazil
Prior art keywords
microcapsules
dry weight
modified release
poorly soluble
coating film
Prior art date
Application number
BR0312988-8A
Other languages
English (en)
Inventor
Florence Guimberteau
Catherine Castan
Remi Meyrueix
Gerard Soula
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of BR0312988A publication Critical patent/BR0312988A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MICROCáPSULAS COM LIBERAçãO MODIFICADA DE PRINCìPIOS ATIVOS POUCO SOLúVEIS PARA A ADMINISTRAçãO PER OS". A presente invenção refere-se a microcápsulas que permitem a liberação modificada de modo confiável e industrialmente reprodutível de um princípio (PA) pouco solúvel na água, com exclusão dos anti-hiperglicêmicos. Cada uma dessas microcápsulas compreende um núcleo de PA pouco solúvel e uma película de revestimento aplicada sobre o núcleo. Seu diâmetro médio é inferior a 1000 mícrons. A película de revestimento contém um polímero filmogênico (P1) insolúvel nos líquidos do trato gastrointestinal; um polímero hidrossolúvel (P2); um plastificante (PL); e eventualmente um agente tensoativo (TA) lubrificante. Essa película de revestimento representa pelo menos 4 % p/p seco de sua massa total, e seus componentes P1, P2, PL satisfazem às seguintes características: fração mássica em peso seco de P1 em relação à massa total do revestimento, compreendida entre 40 e 90%; fração mássica em peso seco de P2/P1+P2 compreendida entre 15 e 60 %; fração mássica em peso seco de PL/P1+PL compreendida entre 1 e 30 %. A invenção também refere-se às aplicações das ditas microcápsulas em galênica.
BR0312988-8A 2002-07-26 2003-07-28 Microcápsulas com liberação modificada de princìpios ativos pouco solúveis para a administração per os BR0312988A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209530A FR2842735B1 (fr) 2002-07-26 2002-07-26 Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
PCT/FR2003/002384 WO2004010984A2 (fr) 2002-07-26 2003-07-28 Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os

Publications (1)

Publication Number Publication Date
BR0312988A true BR0312988A (pt) 2005-06-21

Family

ID=30011527

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312988-8A BR0312988A (pt) 2002-07-26 2003-07-28 Microcápsulas com liberação modificada de princìpios ativos pouco solúveis para a administração per os

Country Status (13)

Country Link
US (2) US20060275376A1 (pt)
EP (2) EP1524969A2 (pt)
JP (1) JP2005535680A (pt)
KR (1) KR20050026518A (pt)
CN (1) CN1681483B (pt)
AU (1) AU2003269068B2 (pt)
BR (1) BR0312988A (pt)
CA (1) CA2493464C (pt)
FR (1) FR2842735B1 (pt)
IL (1) IL166431A0 (pt)
MX (1) MXPA05001076A (pt)
WO (1) WO2004010984A2 (pt)
ZA (1) ZA200500734B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
FR2869624B1 (fr) * 2004-04-28 2006-06-09 Inst Francais Du Petrole Structure et revetement auto-reparables pour milieu corrosif
FR2869764B1 (fr) * 2004-05-07 2006-07-21 Olivier Roche Complement nutrionnel liquide et procede de preparation de ce complement
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
EP1850835A1 (fr) * 2005-02-21 2007-11-07 Flamel Technologies Forme pharmaceutique orale de losartan
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
AU2009301994B2 (en) 2008-10-08 2016-10-20 Bioplus Life Sciences Pvt. Ltd. Sustained release drug delivery system
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
FR2945945B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Procede de preparation de particules creuses et leurs applications
SG10201504529WA (en) * 2010-03-09 2015-07-30 Alkermes Pharma Ireland Ltd Alcohol Resistant Enteric Pharmaceutical Compositions
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2012120366A1 (en) * 2011-03-09 2012-09-13 Ideal Cures Pvt. Ltd. Novel moisture barrier immediate release film coating composition
KR101811301B1 (ko) 2011-05-24 2017-12-26 삼성전자주식회사 반도체 패키지
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US20150299516A1 (en) * 2012-11-26 2015-10-22 Progel Pty Ltd Coating composition
AU2013351920B2 (en) 2012-11-29 2018-08-23 Progel Pty Ltd Microparticles comprising a probiotic, cross-linkable reagent, a denatured protein, polyol plasticiser and trehalose
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
JP6504548B2 (ja) 2014-02-21 2019-04-24 プリンシピア バイオファーマ インコーポレイテッド Ｂｔｋ阻害剤の塩および固体形態
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
CA2971109A1 (en) * 2014-12-24 2016-06-30 Principia Biopharma Inc. Site specific dosing of a btk inhibitor
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
AU2016308953B2 (en) 2015-08-20 2020-09-10 Glytec, Llc Diabetes management therapy advisor
AU2016388308B2 (en) 2016-01-20 2022-08-04 Theravida, Inc. Methods and compositions for treating hyperhidrosis
CN105581996B (zh) * 2016-02-23 2018-03-27 广西梧州制药（集团）股份有限公司 一种去水卫矛醇微囊及其制备方法
BR112018077503A2 (pt) 2016-06-29 2019-04-09 Principia Biopharma Inc. formulações de liberação modificada de 2-[3-[4-amino-3-(2-fluoro-4- fenoxi-fenil)pirazolo [3,4-d]pirimidin-1-il]piperidino-1- carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il] pent-2-enenitrila
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2313915A1 (fr) * 1976-01-26 1977-01-07 Corneille Gilbert Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
LU85943A1 (fr) * 1985-06-12 1987-01-13 Galephar Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
SE8601624D0 (sv) 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
JPH0236571B2 (ja) 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
IT1227899B (it) * 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
GB8913889D0 (en) * 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
JPH0873345A (ja) 1994-09-05 1996-03-19 Terumo Corp 医薬製剤
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
EP0953359A4 (en) 1996-12-19 2001-12-19 Daiichi Seiyaku Co PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
US5965167A (en) 1997-10-07 1999-10-12 Sanghvi; Pradeepkumar P. Dosage units
IL162023A0 (en) 1998-03-30 2005-11-20 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
EP1117384A1 (en) 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
DE69912311T2 (de) 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
DE60325709D1 (de) * 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
CA2480824A1 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
EP2616050A1 (en) * 2010-09-14 2013-07-24 Nanologica AB Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients

Also Published As

Publication number Publication date
EP2272506A2 (fr) 2011-01-12
WO2004010984A3 (fr) 2004-04-08
EP1524969A2 (fr) 2005-04-27
US8821935B2 (en) 2014-09-02
IL166431A0 (en) 2006-01-15
AU2003269068B2 (en) 2009-01-22
FR2842735B1 (fr) 2006-01-06
ZA200500734B (en) 2006-03-29
CA2493464A1 (fr) 2004-02-05
AU2003269068A1 (en) 2004-02-16
EP2272506A3 (fr) 2013-07-10
CN1681483A (zh) 2005-10-12
JP2005535680A (ja) 2005-11-24
US20070160678A1 (en) 2007-07-12
WO2004010984A2 (fr) 2004-02-05
CA2493464C (fr) 2012-07-03
KR20050026518A (ko) 2005-03-15
US20060275376A1 (en) 2006-12-07
CN1681483B (zh) 2011-12-28
MXPA05001076A (es) 2005-06-06
FR2842735A1 (fr) 2004-01-30

Similar Documents

Publication Publication Date Title
BR0312988A (pt) Microcápsulas com liberação modificada de princìpios ativos pouco solúveis para a administração per os
BR0317810A (pt) Formulação farmacêutica, e, método de fabricar a mesma
Woolfson et al. Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: Optimisation by an artificial neural network
BR9912075A2 (pt) composicão farmacêutica para distribuicão de droga ao cólon e método para preparacão da mesma
SE8602722D0 (sv) Hallbara administreringsformer
BRPI0116659B8 (pt) composição para uso em sistema de distribuição transdérmica de droga e sistema de distribuição transdérmica de droga
BR0011131A (pt) Sistema de ministração terapêutica transdérmica
BRPI0417969A (pt) método para manufaturar um dispositivo de distribuição de droga e dispositivo resultante
BRPI0513904B1 (pt) forma farmacêutica de multipartícula para substâncias ativas de baixa solubilidade e um processo para preparar a forma farmacêutica
BR0009609A (pt) Formas de dosagem de rápida dispersão contendo gelatina de peixe
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
ES2066896T3 (es) Forma oral de farmaco de lipidos.
AR044131A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
AR040681A1 (es) Composicion de tabletas de liberacion sostenida de pramipexol
BR0308761A (pt) Formulação farmacêutica para o ingrediente ativo budesonida
BR9906372A (pt) Composição farmaceutica aquosa para aplicação na mucosa
BRPI0317682B1 (pt) Composição farmacêutica de liberação modificada na forma de uma cápsula
PE20071003A1 (es) Formulacion de suspension de fexofenadina
BR112021004053A2 (pt) composições de filme oral e formas de dosagem tendo perfis de dissolução de ativo precisos
BR0109602A (pt) Glóbulos de liberação controlada contendo estavudina
Ciper et al. Preparation and characterization of novel fast disintegrating capsules (Fastcaps) for administration in the oral cavity
Khan et al. Review on mucoadhesive drug delivery system: novel approaches in modern era
RU2701514C2 (ru) Антивирусная фармацевтическая композиция
BRPI0711871A2 (pt) composições farmacêuticas para liberação sustentada de fenilefrina
BR0207497A (pt) Dispositivo que pode ser retido em uma geometria para cavidades corporais

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 6, 8, 11, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.